[Announcement+] Pharmicell "Q1 Sales 9.5 Billion KRW... Nucleoside Thank You"

[Asia Economy Reporter Hyunseok Yoo] Pharmicell announced on the 13th that its sales in the first quarter increased by 16.3% compared to the same period last year, reaching 9.5 billion KRW. Operating profit decreased by 12% to 754 million KRW, while net profit recorded 900 million KRW, continuing its profitability trend.

By business division, the Chemical Division, which produces active pharmaceutical ingredients (nucleosides, mPEG), recorded sales of 8.8 billion KRW, a 25% increase compared to the same period last year. In particular, looking at each product, nucleoside sales showed a remarkable growth, increasing by 28% year-on-year to 3.2 billion KRW.

A Pharmicell representative stated, “Since nucleosides began full-scale shipments from March, we expect sales to continue to grow in the second quarter as well. This year, orders for nucleosides, which are the main raw materials used in virus diagnostic kits, infectious disease diagnostic reagents, and gene therapy new drugs, have rapidly increased due to the rising demand for COVID-19 diagnostic kits and the growth of the gene therapy market using RNA. Based on current order volumes, we have already secured sales of 7.8 billion KRW, surpassing last year’s total nucleoside sales of 7.1 billion KRW.” He added, “mPEG also began commercial supply to the multinational pharmaceutical company UCB from March, and since we secured about 3.4 billion KRW in orders in the second quarter alone, we expect sales to continue increasing. The total mPEG sales, which were 2.9 billion KRW last year, are expected to exceed 5 billion KRW this year.”

Pharmicell plans to enhance corporate value through continuous investment in research and development of its bio business, based on the stable growth of its chemical business. In particular, it expects that the commercialization clinical entry of treatments for liver cirrhosis, erectile dysfunction, and next-generation anticancer immunotherapy vaccines will serve as additional growth drivers.

This content was produced with the assistance of AI translation services.